A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

Eisai Co., Ltd.0 个研究点目标入组 60 人开始时间: 2013年7月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) With definitive diagnosis of Down syndrome
•(2) Have greater than or equal to 3 of the following 4 symptoms; Survey on Sudden Regression, Motor retardation, mutism, social withdrawal, sleep disorder
•(3) Must have a family member or a caregiver who will be able to support the subject during the study by providing necessary study information to the subject, assisting treatment compliance, and accompanying the subject to all scheduled visits, supporting study-related tests for the efficacy and safety assessments throughout the study period

•1.Suspected to have progressive neuropsychiatric disease (e.g., neurodegenerative disorder and progressive tumor) evidenced by MRI or CT within 1 year before the Pre-randomization Phase (if not tested within 1 year before the Pre-randomization Phase, reconfirm during the Pre-randomization Phase).
•2.Have a history of significant neurological disorders such as stroke, brain tumor, encephalitis, meningitis, normal pressure hydrocephalus, brain trauma accompanying unconsciousness, and experience of brain surgery causing unsolved deficiency
•3.Previously diagnosed with autism
•4.With evidence of atlantoaxial subluxation, or underwent surgical operation for atlantoaxial subluxation within 2 years
•5.Have seizure symptoms within 2 years or used antiepileptic drug within 1 year before enrollment of Pre-randomization Phase.
•6.With severe hearing or visual impairment which may affect regression

发起方